StriVectin Revises Ad With ‘Clear And Conspicuous’ Disclosure
This article was originally published in The Tan Sheet
Executive Summary
The National Advertising Division, reflecting FTC enforcement in 2014 on inadequate disclosures, scrutinized print advertising for StriVectin Intensive Illuminating Serum. The skin care firm will revise the ad to address NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.
You may also be interested in...
Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.
FTC: All Advertisers Should Heed Lessons From “Operation Full Disclosure”
On the heels of FTC’s “Operation Full Disclosure,” which resulted in 60 warning letters, commission officials advise all advertisers to pay close attention to their disclosures and ensure they are clear and conspicuous. The initiative included review of 1,000 national television and print ads, and the agency says it will continue to monitor the advertising landscape for inadequate disclosure use.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.